| [1] |
Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast-risk assessment and management options[J]. N Engl J Med,2015,372(1):78-89.
|
| [2] |
Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease[J]. Endocr Relat Cancer,2001,8(1):47-61.
|
| [3] |
Santen RJ, Mansel R. Benign breast disorders[J]. N Engl J Med,2005,353(3):275-285.
|
| [4] |
Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression[J]. J Pathol,2011,223(2):307-317.
|
| [5] |
Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study[J]. J Clin Oncol,2007,25(19):2671-2677.
|
| [6] |
Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation [J]. EMBO J,2004,23(7):1547-1556.
|
| [7] |
Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation [J]. EMBO J,2002,21(22):6236-6245.
|
| [8] |
李小曼, 徐红德, 蔺美娜, 等. DNA 损伤修复反应的双刃剑效应在肿瘤与衰老发生发展中的作用[J]. 中国细胞生物学学报,2013,35(2):134-140.
|
| [9] |
Lakhani SR, Ellis LO, Schnitt SJ, et al. WHO classification of tumours of the breast[M]. Lyon: IARC Press,2012:88.
|
| [10] |
Sinha VC, Qin L, Li Y. A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis[J]. Mol Cancer Res,2015,13(2):231-238.
|
| [11] |
李玉梅, 吴穷, 秦叔逵. MDM2 在恶性肿瘤中的研究进展[J]. 临床肿瘤学杂志,2012,17(3):277-280.
|
| [12] |
Wan L, Lu X, Yuan S, et al. MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors[J]. Cancer Cell,2014, 26(1):92-105.
|
| [13] |
Shi A, Dong J, Hilsenbeck S, et al. The status of STAT3 and STAT5 in human breast atypical ductal hyperplasia [J]. PLoS One,2015,10(7):e0132214.
|
| [14] |
Haricharan S, Dong J, Hein S, et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy[J].Elife,2013,2: e00996.
|
| [15] |
Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges[J]. J Natl Cancer Inst,2004,96(12):906-920.
|
| [16] |
Partridge AH, Elmore JG, Saslow D, et al. Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop[J]. CA Cancer J Clin,2012,62(3):203-210.
|
| [17] |
Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study[J]. Cancer,2005,103(9):1778-1784.
|
| [18] |
Lee RJ, Vallow LA, McLaughlin SA, et al. Dutal carcinoma in situ of the breast[J]. Int J Surg Oncol,2012,2012:123549.
|
| [19] |
Abba MC, Gong T, Lu Y, et al. A molecular portrait of high-grade ductal carcinoma in situ[J]. Cancer Res,2015,75(18):3980-3990.
|
| [20] |
Mardekian SK, Bombonati A, Palazzo JP. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions[J]. Hum Pathol,2016,49:114-123.
|
| [21] |
Volinia S. Unexpected findings of variability in microRNAs suggest roles in human genetics[J]. Genome Med,2012,4(8):69.
|
| [22] |
Beretov J, Wasinger VC, Millar EK, et al. Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LCMS/MS approach [J]. PLoS One,2015,10(11): e0141876.
|
| [23] |
Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors[J]. Cancer Cell, 2007, 12(5):479-491.
|
| [24] |
Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue[J]. Cancer Res,2005,65(5):1792-1799.
|
| [25] |
Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis[J]. J Natl Cancer Inst,2010,102(9):627-637.
|
| [26] |
Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer[J]. Br J Cancer,2006,94(8):1154-1163.
|
| [27] |
Knudsen ES, Pajak TF, Qeenan M, et al. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression[J]. J Natl Cancer Inst,2012,104(23):1825-1836.
|
| [28] |
Elsarraj HS,Hong Y,Valdez KE,et al. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion[J]. Breast Cancer Res,2015,17:128.
|
| [29] |
Scribner KC, Behbod F, Porter WW. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s)[J]. Oncogene,2013,32(21):2631-2639.
|
| [30] |
Rizki A, Bissell MJ. Homeostasis in the breast: it takes a village[J].Cancer Cell,2004,6(1):1-2.
|
| [31] |
Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer[J]. Cancer Cell, 2004,6(1):17-32.
|
| [32] |
Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition[J]. Cancer Cell,2008,13(5):394-406.
|